Log in or Sign up for Free to view tailored content for your specialty!
Rheumatoid Arthritis News
Autoimmune disorders associated with AF risk
Autoimmune disorders were associated with elevated atrial fibrillation risk, particularly in women, according to a study published in EP Europace.
RA studies lag in examining comorbid populations
A slew of recent clinical trials and the continued development of new treatments have ensured that the state of rheumatoid arthritis treatment is more advanced than ever before.
Log in or Sign up for Free to view tailored content for your specialty!
‘Trying not to overdo it’: What to tell patients about gout flares and holiday feasts
The holidays for many people represent a time of indulgence in food and drink, but for patients with gout, these feasts can be veritable minefields that can trigger painful flares.
Osteoporosis prevalence remains high in patients with rheumatoid arthritis
Osteoporosis remains highly prevalent among patients with rheumatoid arthritis despite advancements in prevention and treatment, according to data published in Scientific Reports.
Hoping for a biosimilar ‘sea change’: Rheumatologists weigh 2023 end of Humira exclusivity
In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.
Treating patients with RA must include management of comorbid conditions
PHILADELPHIA — When analyzing patients with rheumatoid arthritis based on their comorbidities, certain groups experienced differing survival outcomes when compared with the expected mortality of the general population.
Patients with RA treated with upadacitinib demonstrated improvements as early as week 1
PHILADELPHIA — Patients with rheumatoid arthritis who were treated with upadacitinib demonstrated improvement in pain, fatigue and morning stiffness from week 1 through week 12, according to data presented at ACR Convergence 2022.
FDA approves Fresenius Kabi’s Idacio as eighth adalimumab biosimilar
The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.
PCPs report feeling uncomfortable making early diagnosis of rheumatoid arthritis
PHILADELPHIA — Although most primary care physicians understand the importance for early diagnosis and management of rheumatoid arthritis, there is discomfort with making the initial diagnosis, a speaker said at ACR Convergence 2022.
Patients with IMIDs, myocardial infarction at higher risk for death, heart failure
Patients with rheumatic immune-mediated inflammatory disease who experience myocardial infarction are more likely to die or experience heart failure vs. patients without immune-mediated inflammatory disease, according to data.
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read